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Introduction
As a result of changes to European Union (EU) legislation facilitating 
the non-commercial movement of pet animals within the EU, it 
is expected that there will be an increase in the number of pets 
travelling to and from accredited countries. Many of these animals will 
be exposed to, and infected with, microbial and parasitic organisms 
currently exotic to Ireland, and veterinary surgeons will be required 
to diagnose, treat and prevent the exotic diseases caused by those 
organisms. This paper aims to review information on the most 
relevant diseases that may be acquired by travelling pets. 
Rabies
Rabies is a viral disease affecting the central nervous system of 
mammals. Dogs, cats, and wildlife species such as foxes and bats are 
important hosts for the virus, with dogs constituting the greatest risk 
to humans. The rabies virus is an enveloped RNA Lyssavirus, with 
multiple genotypes. Contamination of a bite wound with infected 
saliva accounts for the majority of cases. The incubation period ranges 
from ten days to four months (three to eight weeks in the dog and 
four to six weeks in the cat) and varies with the anatomical location 
(particularly, proximity to the spinal cord), degree of innervation at 
the site of infection, and the dose of virus inoculated. 
Pathogenesis and clinical signs
The virus multiplies in muscle fibres and connective tissue at the 
site of infection and may remain in situ for days to months. It then 
enters adjacent nerves, spreads to the central nervous system (CNS) 
and then distally along peripheral nerves to other parts of the body 
including the salivary glands. Salivary shedding of virus may occur 
five to 13 days before clinical signs appear in dogs, and for one to 
two days before clinical signs in cats. Damage to motor neurones 
causes flaccid paralysis and direct damage to CNS is compounded by 
immune-mediated damage. 
Clinical signs are variable but commence with a “prodromal” stage of 
two to three days duration marked by a sudden temperament change 
that may be missed by the owner. Normally friendly dogs may hide 
while shy dogs may show a sudden display of affection. Hyperaesthesia 
may be present at the site of the bite wound. The prodromal stage is 
followed by one of two syndromes, referred to as “dumb” or “furious” 
rabies. “Dumb” rabies is more common in rabid dogs but some may 
alternate between “dumb” and “furious” forms. In “dumb” rabies, the 
clinical course is often shorter but, in both forms, death occurs three 
to seven days after the end of the prodromal stage. Dogs with the 
“dumb” syndrome may have an apprehensive appearance, may snap at 
imaginary objects although they will rarely bite unless provoked. In the 
“furious” syndrome, dogs become restless, irritable, pace continuously 
and may run aimlessly for long distances if not restrained. If restrained, 
they may display inappropriate, uncontrolled signs of “rage”, attacking 
cage bars or furniture. In both syndromes, progressive hind limb 
weakness with ascending paralysis develops in association with cranial 
nerve palsies. Clinical signs include pupillary dilation and loss of the 
corneal reflex, whilst mandibular and glossal paralysis is manifested 
by profuse salivation and dysphagia. Laryngeal paresis may result in 
hoarse barking (dysphonia).
The signs shown by cats resemble those in dogs but the furious 
form occurs in about 75% of cases. The prodromal stage rarely 
lasts for more than 24 hours and the furious stage lasts for one to 
four days. Rabid cats display hypersensitivity to sensory stimuli and 
often retreat into hiding from which they may attack humans and 
other animals. Pupillary dilation, protrusion of claws and continuous 
hoarse vocalisation develop. Hind limb ataxia is followed by ascending 
paralysis and death.
Diagnosis
Rabies is a notifiable disease and all dogs and cats with compatible 
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clinical signs (particularly if they have travelled overseas) should 
be isolated, securely confined and the appropriate government 
authority informed. There is obvious danger in handling suspect 
dogs and cats and premortem tests are not considered appropriate 
for  rabies  diagnosis  in  UK  and  Ireland.  Diagnosis  is  made  by 
postmortem histological examination of the brain at specialised 
facilities. Histologically, most cases show a necrotising encephalitis, 
ganglioneuritis, mononuclear cell perivascular cuffing, intracytoplasmic 
inclusions (Negri bodies), and the diagnosis is confirmed using direct 
fluorescent antibody testing of tissue which is both rapid and sensitive. 
Specific polymerase chain reaction (PCR) techniques have been 
developed also.
Treatment and prevention 
No attempt should be made to treat suspected cases. Currently 
(2005), only killed vaccines are licensed for dogs and cats in the UK 
and Ireland and they induce a high level of protection against the 
disease. Other vaccines may be licensed in the future. Vaccination 
can be given from four weeks of age, assuming the dam has not been 
vaccinated. Booster vaccination is given every one to two years 
depending on the species being vaccinated and the vaccine used.
Rabies  virus  is  inactivated  by  UV  light,  heat,  detergents  and 
disinfectants. In potential human exposure, immediate treatment 
of bite wounds with detergents, soap or quaternary ammonium 
compounds (1% to 4% solution) significantly reduces the risk of 
infection. 
Leishmaniosis
Leishmaniosis is an important disease of dogs that is endemic in the 
Mediterranean areas of Europe, the Middle East and many tropical 
and subtropical areas of the world. In Europe, the aetiological agent of 
canine leishmaniosis is an intracellular protozoan parasite, Leishmania 
infantum, which is transmitted by sandflies of the genus Phlebotomus. 
In non-endemic areas of northern Europe, the occurrence of canine 
leishmaniosis is increasing rapidly due to increased mobility of infected 
dogs. This is particularly marked in countries where quarantine 
regulations have been relaxed for movement of dogs from leishmania-
endemic European countries. In addition, there are reports that 
potentially competent sandflies are being identified north of the 
traditional endemic areas such as in southern Germany; should 
temperatures rise in southern Ireland and England, conditions may 
become appropriate for the establishment of vectors. In several 
European countries, including the UK, L. infantum infections are 
already being reported in dogs that have never travelled to endemic 
areas (autochthonous infection) and canine leishmaniosis has spread 
extensively  throughout  North America  in  foxhounds  without 
confirmed involvement of a recognised sandfly vector. Non-vector 
transmission has been confirmed in dogs receiving infected blood 
transfusions and amongst human intravenous drug users who share 
infected needles. Vertical and direct transmission is also suspected in 
some cases. 
Pathogenesis and clinical signs 
In endemic areas dogs become exposed almost immediately. Some 
will develop protective immunity, some remain sub-clinically affected 
and may relapse later, and others develop the classic clinical syndrome 
at a young age. The disease has a chronic waxing and waning course 
and the incubation period may vary from several months to years. 
The parasite stimulates an overactive and ineffective B lymphocyte 
response at the same time as suppressing macrophage activation. This 
allows spread of the parasites in the face of massive production of 
immunoglobulins and immune complexes. Both leishmania-specific and 
non-specific antibodies, including autoantibodies, are produced.
Non-specific signs of disease include a history of lethargy, weight 
loss,  polydipsia,  diarrhoea,  and  partial  anorexia.  Generalised 
lymphadenopathy  is  common.  Cutaneous  signs  are  of  major 
significance and include periocular alopecia, hyperkeratosis of the foot-
pads, excessive growth of claws and exfoliative dermatitis producing a 
characteristic silvery scale prominent on the dorsum of the nose, 
periocular region and pinnae. Ulcerative and nodular dermatitis 
may occur secondary to vasculitis and granulomatous inflammation. 
Polydipsia  and  weight  loss  due  to  protein-losing  nephropathy 
are common, as are ocular signs due to panophthalmitis. Shifting 
lameness and joint swelling due to immune-mediated polyarthritis 
and Coombs’-positive anaemia may be present. Clinicopathological 
findings include marked proteinuria, hyperglobulinaemia (sometimes 
with monoclonal or biclonal spikes) and occasional antinuclear 
antibody positivity. Concurrent ehrlichiosis is common in endemic 
areas and care should be taken to eliminate coinfection in dogs that 
have bleeding diatheses. 
Diagnosis
Along with typical clinical signs and a history of exposure, definitive 
diagnosis of leishmaniosis is based on microscopic identification of 
the parasite in stained (Giemsa or Leishman) aspirates of lymph node, 
bone marrow or spleen, or in skin biopsies. Immunohistochemistry 
may increase the sensitivity of detection in tissue biopsies. Many 
serological techniques are available including immunofluorescent 
antibody test (IFAT), and enzyme-linked immunosorbent assays 
(ELISA) and high titres or rising titres are compatible with active 
infection rather than exposure. Polymerase chain reaction (PCR) 
testing  on  bone  marrow  samples  is  sensitive  and  specific  for 
leishmaniosis but because of tissue localisation has only 60% to 70% 
sensitivity on peripheral blood samples. Real time PCR testing on 
peripheral blood samples has increased sensitivity and quantification 
allows monitoring of therapy.
Treatment and control
The zoonotic potential of this disease is considered low without the 
presence of competent vectors but implications should be discussed 
with owners, particularly if there is an immuno-compromised 
individual in the household. The documented transmission of infection 
between dogs in the absence of the sandfly vector has unknown 
zoonotic implications.
Prior to therapy, the extent of systemic disease should be fully 
evaluated and appropriate supportive treatment given. Although other 
drugs may be used in some countries, treatment most commonly 
recommended is a combination of allopurinol and a pentavalent 
antimonial drug such as meglumine antimonate (Table 1). In non-
endemic areas, allopurinol is used initially with the addition of an 
antimonial course if there is poor response. Allopurinol treatment is 
continued on a long-term basis to maintain remission. Treatment could 
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be suspended if serology and PCR on bone marrow are negative. The 
drug is inexpensive and major side effects with long-term therapy 
have not been reported. Concurrent treatment for ehrlichiosis 
may be necessary. Prognosis is dependent on the severity of organ 
dysfunction, particularly of the kidneys, at the time of diagnosis. If the 
dog is a treatment candidate, the prognosis for parasitological cure is 
guarded although the prognosis for control of the clinical expression 
of disease is good. 
Vaccination is not yet available for leishmaniosis. Sandfly biting is 
reduced by using synthetic pyrethroids (permethrin and deltamethrin), 
and animals should be housed during peak sandfly activity. 
Feline leishmaniosis
Natural infection and clinical disease in domestic cats caused by 
Leishmania spp appears to be uncommon but has been reported in 
areas where canine infection is high. Feline leishmaniosis is presumed 
to be sandfly-transmitted; however, the vector is unknown and the 
epidemiology of the disease has not been investigated.
Systemic clinical disease and asymptomatic infection due to L. infantum 
and other species are reported and wild cats have been incriminated 
as reservoirs for Leishmania spp. in endemic Mediterranean countries. 
Cutaneous lesions alone have been reported in association with 
unspecified Leishmania spp in Europe, South America and in the 
southern USA. The clinical presentation is similar to that seen in 
dogs although the small number of cases makes the association of 
infection and clinical signs difficult to interpret. Cutaneous lesions 
include diffuse areas of alopecia and granulomatous dermatitis of the 
head, scaling and pinnal dermatitis, ulceration and nodules. Systemic 
involvement  associated  with  jaundice,  vomiting,  hepatomegaly, 
splenomegaly, lymphadenomegaly, membranous glomerulonephritis 
and granulomatous gastroenteritis has been reported. The same 
microscopic and molecular tests used for diagnosis of canine 
leishmaniosis can be used for cats. There are no serological tests 
validated for cats and therapeutic agents for leishmaniosis in cats have 
not been investigated. Synthetic pyrethroids should not be used in 
cats and prevention is limited to decreased exposure to sandfly bites. 
Babesiosis
Babesiosis is caused by protozoan parasites of the genus Babesia 
that infect erythrocytes and are transmitted by Ixodid ticks. The 
classification of canine babesiae is currently undergoing change as 
the new species and subspecies are characterised by molecular 
technology. Two broad groups (large and small babesiae) infect dogs. 
The Babesia canis group is characterised by larger organisms, and 
comprises three distinct subspecies. B. canis canis is a moderately 
pathogenic organism transmitted by the tick Dermacentor reticulatus 
and it is the major cause of clinical babesiosis in Europe. B. canis vogeli, 
transmitted by the tick Rhipicephalus sanguineus, is the least pathogenic 
canine babesia and is widely distributed in the tropical and subtropical 
regions of most continents including Europe, Asia, Australia, northern 
Africa and USA. The third subspecies, B. canis rossi, is geographically 
restricted to southern Africa. 
The small babesiae infecting dogs are diverse, of moderate to high 
pathogenicity, and new species are being increasingly recognised in 
Europe. Until recently, B. gibsoni was the only recognised babesial 
organism in this group. It has multiple tick vectors and is distributed 
throughout Asia, northern Africa, southern Europe and areas of the 
USA and Australia. However, other small “babesial” organisms have 
been identified in dogs with clinical babesiosis, including those in 
Spain and Hungary that resemble B. microti. In the UK, the tick vectors 
(D. reticulatus and R. sanguineus) are present although localised in 
distribution; to date, dogs reported with babesiosis have had a history 
of exposure in other countries of Europe. Non-tick transmission 
through infected blood transfusions and transplacental transmission 
have been reported, although uncommonly. Transmission of B. gibsoni 
from dog to dog through biting has also been suggested. The babesiae 
infecting companion animals are not considered zoonotic, although 
the zoonotic potential of the recently identified small babesiae related 
to B. microti remains undetermined. Disease outbreaks of B. canis canis 
in Europe are seasonal, and related to the biology of Dermacentor 
ticks. Coinfections with Ehrlichia species and Leishmania require 
consideration.
Pathogenesis and clinical signs 
The  clinical  outcome  following  infection  is  dependent  on 
the pathogenicity of the Babesia species and strain, and the age, 
immune status and breed of the infected dog. Susceptibility amongst 
greyhounds, Pitbull terriers and Staffordshire Bull Terriers has been 
reported for B. gibsoni infection, although this may reflect increased 
chance of infection through biting. 
In dogs (Figures 1, 2 and 3), the most common clinical presentation 
in  Europe  is  uncomplicated  disease  involving  an  acute  onset 
haemolytic anaemia caused by B. canis canis or B. gibsoni. However, 
susceptible non-immune travelling dogs may develop hyperacute 
disease. It is likely that a percentage of dogs develop subclinical 
infection that may recrudesce at any stage after exposure. 
Haemolytic anaemia is the major clinical finding and may involve 
both intravascular and extravascular haemolysis due to parasite 
damage  to  erythrocytes,  metabolic  changes  in  erythrocyte 
membranes leading to increased osmotic fragility, and antibody-
mediated erythrophagocytosis. Associated clinical signs include 
pyrexia, haemoglobinuria, mucous membrane pallor, splenomegaly, 
FIGURE 1: Five-year-old Labrador retriever recently returned from France 
with babesiosis, showing severe depression and weakness.
FIGURE 2: Blood smear made from a sample 
obtained from an ear-tip prick showing B. gibsoni 
within Diff Quik-stained erythrocytes. Original 
magnification x1,000.
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lymphadenomegaly, anorexia, vomiting, and lethargy. Thrombocytopenia 
is common although rarely of sufficient severity to cause bleeding. 
Blood samples may autoagglutinate in saline and up to 85% of dogs 
may be Coombs’-positive. Jaundice can occur but only late in disease 
and in association with liver dysfunction. Very susceptible dogs infected 
with B. canis canis may develop multiple organ inflammatory syndrome, 
hypotensive shock and disseminated intravascular coagulation. Clinical 
signs may relate to hepatic, renal, and neurological dysfunction. The 
clinical presentation of babesiosis may be complicated by coinfection 
with other tick-borne infectious agents. Thrombocytopenia as a result 
of monocytic ehrlichiosis may complicate babesia-induced haemolytic 
anaemia with haemorrhagic diatheses.
Diagnosis
In dogs with appropriate clinical signs and a history of exposure, 
blood smears stained by Romanowsky or Wright’s methods should be 
examined for intraerythrocytic organisms. Smears should be prepared 
from blood obtained from pricking an ear tip as this increases the 
chance of observing parasitised erythrocytes. However, sensitivity is 
reduced by low level and fluctuating parasitaemia as well as by the 
difficulty in identifying the small babesia species. Serological tests (IFA 
or ELISA) for some babesia species have been developed but they are 
not easily commercially available in Europe and have problems with 
poor sensitivity and specificity. PCR testing of blood samples for all 
Babesia species is highly sensitive and specific for infection and real 
time PCR will be available for quantification of microbial load for 
monitoring purposes.
Treatment and control
The treatment of choice for B. canis canis and B. canis vogeli is 
imidocarb dipropionate although there is not a licensed product 
available in Ireland or UK at present (Table 1). This treatment is 
ineffective against B. gibsoni, which is more successfully treated with a 
combination of ataquarone and azithromycin (Table 1). Other drugs 
used, but left in reserve, include phenamidine isethionate, pentamidine 
isethionate and diminazene aceturate. Infected animals may become 
chronic carriers despite therapy, although the degree to which this 
occurs when exposure is limited in non-endemic countries is not 
confirmed. Supportive therapy for haemolytic anaemia (including fluids 
and cross-matched blood transfusions) may be required and, although 
controversial, a short course of glucocorticoids may be appropriate to 
counter the immune-mediated component of the disease. 
Prevention of babesiosis is dependent on control of the vector 
ticks using fipronil, permethrin or deltamethrin. Owners should be 
encouraged to examine animals daily in order to remove ticks before 
attachment. There is on-going European research into development of 
B. canis vaccines. 
Feline babesiosis
Feline babesiae are poorly characterised. B. felis is primarily found in 
southern Africa and a separate subspecies of B. canis has recently been 
reported in Israeli cats. A report of a large babesia species occurring 
in a cat has been published in India. Separate babesiae infect wild 
Felidae. The tick vectors are unknown. In South Africa, B. felis infection 
has no breed or gender predisposition. The clinical presentation is 
that of chronic regenerative anaemia but adaptation of the cat to the 
anaemic state means that clinical signs may only manifest with stress. 
The most commonly recommended drug for treatment of feline 
babesiosis in South Africa is primaquine phosphate (Table 1). 
Canine monocytic ehrlichiosis
Monocytic ehrlichiosis due to Ehrlichia canis has a global distribution 
in tropical and semi-tropical regions throughout the world and its 
distribution follows that of its vector, the tick Rhipicephalus sanguineus. 
This tick is present in focal areas of the UK, including quarantine 
kennels and has adapted well to households in which there are dogs. 
Monocytic ehrlichiosis is now endemic in central Europe including 
Austria, Switzerland and southern Germany, as well as the southern 
European countries.
Pathogenesis and clinical signs 
Following infection, there is an acute phase of illness (eight to 20 days) 
followed by clinical remission, which may last for years. In susceptible 
animals, a waxing and waning syndrome of chronic ehrlichiosis 
develops associated with bone marrow dysplasia and other immune-
mediated organ damage. Coinfection with Babesia spp. and L. infantum 
is common in endemic areas. In acute canine monocytic ehrlichiosis, 
clinical signs include fever, anorexia, and lymphadenopathy combined 
with a bleeding disorder. Petechiation (Figure 4), epistaxis, intraocular 
bleeding are common due to immune-mediated thrombocytopenia 
and platelet dysfunction. Dogs, which are subclinically infected, may 
relapse intermittently with immunosuppressive episodes. In chronic 
disease, hypergammaglobulinaemia is a feature as are signs of bone 
marrow damage. This may be restricted to platelet precursors but 
varying degrees of non-regenerative anaemia, thrombocytopenia 
and leucopenia may develop in susceptible animals. In the German 
shepherd breed, pancytopenia may be irreversible and fatal. 
Diagnosis
Diagnosis of monocytic ehrlichiosis is based on appropriate clinical 
findings and microscopic identification of aggregations of ehrlichial 
organisms (morulae) in monocytes on a Wright’s stained capillary 
blood smear (from a pricked eartip), buffy coat smear or splenic 
FIGURE 3: Moribund crossbreed dog 
with severe jaundice and multiorgan 
failure due to B. canis infection. 
(Courtesy of Kate Murphy).
3a: Buccal mucosa (top right). 
3b: Skin of medial pinna (top left).
3c: Haemaglobinuria in a cystocentesis 
sample. 
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aspirate. Many serological tests are now available but there is 
considerable cross-reaction with other ehrlicial and rickettsial species 
and a rising titre is required to confirm active infection. Persistent 
antibody production makes monitoring of therapy and interpretation 
difficult. Species-specific PCR tests on EDTA blood and splenic 
aspirates are sensitive and specific, they distinguish between infection 
and exposure, and they identify cases early in disease progression. 
Treatment and control
Supportive therapy with fluids and blood transfusions may be required. 
If life-threatening thrombocytopenia is present, glucocorticoid therapy 
has some rationale as the pathogenesis of the thrombocytopenia has 
an immune-mediated component. Doxycycline or oxytetracycline 
therapy is the treatment of choice for ehrlichiosis (Table 1) for 
21 to 28 days. Imidocarb dipropionate can be given for resistant 
infections although its efficacy is debatable. At present, vaccination 
is not available. Prophylaxis for travelling dogs involves tick control 
using fipronil, permethrin or deltamethrin and owners should 
be encouraged to examine dogs daily to remove ticks prior to 
attachment. 
Feline monocytic ehrlichiosis
Feline ehrlichiosis associated with inclusions in mononuclear cells has 
been reported in cats with seropositivity to and PCR-positivity for E. 
canis. As in other species, monocytic ehrlichiosis in cats is presumed 
to be tick-transmitted. Clinical signs with naturally occurring disease 
include intermittent fever, anorexia, weight loss, vomiting, diarrhoea, 
upper  respiratory  signs  and  muscle  pain.  Clinicopathological 
findings  include  anaemia,  thrombocytopenia,  leucopenia  and 
hyperglobulinaemia. Statistically significant associations between 
clinical signs and positive serology are more limited. Definite diagnosis 
of feline ehrlichiosis is made by demonstration of intramonocytic 
inclusions in, or PCR of, a peripheral blood sample. 
Although controlled therapeutic trials are lacking, administration 
of doxycycline or tetracycline (Table 1) is the treatment of choice 
for feline ehrlichiosis and clinical response is reported to be 
excellent. Control of vectors offers the most appropriate method of 
prophylaxis. 
Canine anaplasmosis (canine cyclic thrombocytopenia)
Canine cyclic thrombocytopenia, caused by Anaplasma (Ehrlichia) 
platys, occurs in several southern European countries, Israel, Taiwan, 
Venezuela and, most recently, Australia. This species of Anaplasma 
has tropism for platelets and it is assumed that it is transmitted by 
R. sanguineus. Pathogenicity is generally low but A. (E.) platys infection 
may play a role in coinfection with other arthropod borne diseases 
such as Babesia or Ehrlichia species which are also transmitted 
by Rhipicephalus. Mild to moderate thrombocytopenia occurs at 
intervals of two to three weeks and is primarily asymptomatic 
unless the dog undergoes surgery or has a concurrent bleeding 
disorder. However, there are reports of a more pathogenic strain 
from Greece and the Middle East. Platelet inclusions are a useful 
means of diagnosis, although species-specific PCR tests have now 
been developed. Considering the cyclic nature and low levels of the 
parasitaemia, molecular diagnosis offers a more sensitive alternative 
to cytology. IFA tests have been developed but are not commercially 
available. Given the asymptomatic nature of the disease, treatment 
may not be necessary although infection is responsive to tetracyclines. 
Vector control, using fipronil, permethrin or deltamethrin, is the most 
appropriate means of prevention.
Heartworm disease (dirofilariosis)
Heartworm infection and disease is caused by the filarial nematode, 
Dirofilaria immitus and is transmitted by mosquitoes of many species. 
Dogs are the primary hosts for D. immitus.
Heartworm infection in cats, although rarely associated with latency, 
is being increasingly recognised in areas where the infection rate in 
dogs is high. Non-patent human infections may occur rarely. Canine 
dirofilariosis is endemic in southern Europe, the Americas, Australia, 
Africa and Asia. In Europe, it is prevalent in focal areas of Portugal, 
Spain, southern France, Italy, Greece and other countries of the 
Mediterranean. At present, heartworm infection is not endemic in 
northern Europe despite the fact that competent vector species are 
present, because larval maturation in the mosquito is inhibited where 
mean summer temperatures are low. At present, areas of temperate 
continental Europe that have higher summer temperatures are more 
at risk for new outbreaks than the UK or Ireland. Another risk for 
establishment is the potential for genetic adaptation for maturation at 
cooler temperatures. Mosquitoes ingest the L1 larvae (microfilariae) 
with a blood meal from an infected dog and, after an obligatory period 
of development, the infective L3 larval stage is injected back into a 
susceptible host. Larvae undergo several moults and migrate through 
host tissues to the right pulmonary artery where they mature to 
adults six to eight months after infection. Adult female heartworms 
are viviparous and produce L1 larvae directly into the systemic 
circulation. Adult heartworms can live for five to six years, and the 
microfilariae for up to two years.
Pathogenesis and clinical signs
Adult worms in the pulmonary artery cause thickening of the vessel 
endothelium and smooth muscle layer. Thromboembolism is initiated, 
causing obstruction of smaller pulmonary vessels and periarterial 
inflammation. Development of pulmonary hypertension may result in 
exercise intolerance, syncope and weight loss. In sensitised animals, 
FIGURE 4: Buccal mucosal petechiation in a clinical 
case of ehrlichosis in a dog (E. canis).
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eosinophilic pneumonitis can be induced by parasite antigen without 
major arterial changes, and immunological destruction of circulating 
microfilariae can occur. Clinical signs may only develop when animals 
undergo cardiovascular stress, have heavy parasite burdens or 
sensitivity to parasite antigens. Early signs are exercise intolerance 
and coughing. Dyspnoea, weight loss and pulmonary haemorrhage may 
occur in more severe cases. Signs of right-sided cardiac failure (jugular 
distension, hepatomegaly) may occur later in disease or severe 
infestations. A rare (caval) syndrome may occur when susceptible 
animals are infected with high worm burdens all maturing at a similar 
time, causing obstruction of the vena cava and the pulmonary outflow 
tract. Clinical signs are characterised by intravascular haemolysis due 
to erythrocyte fragmentation, collapse, hypotension, pale mucous 
membranes,  tricuspid  murmur,  dysrhythmias,  haemoglobinuria, 
hepatomegaly and sudden death. 
Diagnosis
Diagnosis of dirofilariosis involves microscopic examination of EDTA 
blood for microfilariae using the modified Knott’s filter test. Other 
species of non-pathogenic filarial worms (Dipetalonema reconditum and 
Dirofilaria repens) produce microfilaraemia and may give false-positive 
results unless proper parasitological identification is available. D. 
immitiis infections caused by single sex infections, immature burdens, 
or immune-mediated destruction of microfilaria result in false-
negative results. ELISA testing based on detection of D. immitis uterine 
antigen is available from most clinical diagnostic laboratories, and is 
specific and sensitive except in single sex infections. Antibody testing 
for D. immitis lacks specificity for canine patients. Diagnostic imaging 
of clinical cases reveals tortuous, pruned arteries (especially of the 
right caudal lobe), interstitial and alveolar infiltrates and right-sided 
cardiac enlargement with or without a pulmonary artery bulge. 
Echocardiography may allow visualisation of the adult worms and is 
the diagnostic method of choice in caval syndrome.
Treatment and control
Symptomatic treatment of heart failure and judicious management 
of allergic pulmonary disease with prednisolone is appropriate prior 
to administration of parasiticidal drugs. Prednisolone should be 
TABLE 1: Recommended treatments for exotic arthropod-borne diseases of dogs and cats
Disease  Generic   Recommended   Interval and duration 
  product  dose rates  of therapy  Notes/toxicity
LEISHMANIOSIS 
  Allopurinol (purine analogue)  Dogs: 10-15mg/kg PO  q12-24h   Increase uric acid 
  Meglumine antimonate   Dogs: 100mg/kg SC  q24-48h for 20-40 days  levels
  (pentavalent antimonial)      Pain, swelling at
        injection site,
        renal dysfunction, 
        increased liver    
        enzymes.
BABESIOSIS
B. canis canis  Imidocarb dipropionate  5.0-6.6mg/kg IM or SC  Once, then repeat 2-3 weeks  Uncommon salivation,
B. gibsoni  Ataquavone in combination  13.3 mg/kg PO +  q8hrs +  lacrimation, diarrhoea, 
  with azithromycin  10mg/kg PO  q24hrs for 10 days  vomiting, 
B. felis  Primiquine phosphate   0.3mg/kg PO  q24hrs for 14 days  muscle tremor,  
        pain on injection.
EHRLICHIOSIS
  Doxycycline  Dogs: 5-10mg/kg PO  q12-24h for 14-21 days  Stain teeth in first
    Cats: 5mg/kg PO    month of life and
ANAPLASMOSIS        in last trimester
  Oxytetracycline  Dogs and cats 7-11mg/kg   q8h for 14-21 days  pregnancy. Anorexia
    IM,SC  q8h for 14-21 days  especially in cats, 
    Dogs 25mg/kg PO    vomiting, diarrhoea.
DIROFILARIOSIS 
  Melarsomine  Protocol A 2.2mg/kg IM  Once then again at 3h  Dosing protocol
    or    dependant on
    Protoocol B 2.5mg/kg IM  Once then repeat at 24h  clinical classification.
        Subclinical disease:
        Protocols A or B
        Moderate disease:
        Protocol B
        Severe: Single2.5mg/kg
        treatment followed by
        Protocol B 1-2  
        months later. 
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withdrawn 48 hours prior to parasiticidal therapy to increase efficacy 
of adult nematode kill. Parasiticidal therapy is associated with potential 
adverse effects, particularly pneumonitis and thromboembolism, 
following death of the adult worms. At present, melarsomine is the 
adulticidal drug of choice in Europe (Table 1). Dogs should be cage-
rested after therapy to minimise thromboembolism, and prednisolone 
can be reintroduced to control inflammatory complications. Prognosis 
in early to moderately severe heartworm disease is good. Use of 
a microfilaricidal drug following adulticide therapy is debatable in 
non-endemic areas as there is minimal risk of transmitting infection. 
However, persistent microfilaraemia may incite immune-mediated 
damage and ivermectin or milbemycin can be used as microfilaricides. 
Caval syndrome is an emergency and adult worms must be removed 
with forceps from the vena cava and heart via jugular venotomy. 
Survival rates are less than 50%.
Prevention is primarily achieved by administration of drugs that kill 
migrating larvae and drugs available in Europe include selemectin and 
milbemycin oxime alone and in combination with other drugs (Table 
1). Dogs travelling to endemic countries should begin preventative 
therapy seven to ten days prior to travel and the treatment duration 
should ensure that they are covered completely while they are abroad. 
Where there is any possibility that dogs may already be infected, 
testing should be performed as adverse or unexpected reactions may 
occur if preventative medications are administered to infected cases. 
Routine prophylaxis for puppies can start from six to eight weeks of 
age. 
Feline dirofilariosis 
Cats may develop non-patent infections in areas of high endemicity. 
They have low worm burdens without production of microfilariae. 
Immune-mediated pulmonary disease may result and clinical signs 
include dyspnoea, coughing, weight loss, vomiting and sudden death. 
Non-patent infection limits the usefulness of diagnostic tests and 
there is a role for antibody testing in feline patients with single or 
low worm burdens. Echocardiography is particularly useful as part of 
the diagnostic regime in feline dirofilariosis. Parasiticidal treatment is 
problematic as the arsenical preparations used in dogs are particularly 
toxic for cats. Symptomatic treatment of associated pulmonary disease 
with corticosteroids and cage rest is recommended. Selemectin and 
milbemycin are licensed for cats for heartworm prevention in the UK.
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